stock-mb-logo-androidstock-mb-logo-ios
Stock Screener App
Gratuito - Play StoreApp Store
InstallareInstallare
logo
Dyne Therapeutics IncDYN
$18.054.34%0.75
Dopo l'orario di chiusura: 18.050.00 0.00%

Dyne Therapeutics Inc (DYN)

Date: 2026-11-03 16:00O: 17.53H: 18.15L: 17.31C: 18.05Vol: 2.810M
Precedente Chiudi:
$17.30
Aprire:
$17.53
Volume 24 ore:
2,810,077
Volume relativo:
1.31
Capitalizzazione di mercato:
$3.37B
Reddito:
-
Utile/perdita netta:
-$451.71M
Rapporto P/E:
-
EPS:
-$3.23
Flusso di cassa netto:
-$462.19M
1W Prestazione:
+6.55%
1M Prestazione:
+18.75%
6M Prestazione:
+3.80%
1Y Prestazione:
-25.13%
Intervallo 1D:
$17.31$18.15
Intervallo di 1 settimana:
$16.11$18.15
Portata 52W:
$14.00$27.31

Profilo aziendale di Dyne Therapeutics Inc (DYN)

Nome
Dyne Therapeutics Inc
Settore
Healthcare
Industria
Biotechnology
Telefono
(781) 786-8230
Indirizzo
1560 TRAPELO ROAD, WALTHAM, USA
Dipendente
258
X
-
Prossima data di guadagno
2026-11-04
Ultimi documenti SEC
SEC
Discussioni di DYN su X
X

 

Cap. di mercato

 

Reddito

 

Reddito netto

 

Flusso di cassa

 

EPS

 

Dyne Therapeutics Inc Azioni (DYN) Upgrade e downgrade

DataAzioneAnalistaModifica della valutazione
2026-10-28DowngradeOppenheimerOutperform → Perform
2026-09-09DowngradeJP MorganNeutral → Underweight
2026-07-23IniziatoCantor FitzgeraldOverweight
2026-06-26IniziatoTD CowenBuy

Dyne Therapeutics Inc Azioni (DYN) Dati Finanziari

PeriodoAndamentoFY 2025FY 2024FY 2023FY 2022FY 2021
Data di fine periodo2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenue USD (M)--0.000.000.00
Research and development USD (M)398.33281.41210.76142.76121.31
Operating expenses USD (M)468.18343.89242.16170.96150.03
Operating income USD (M)-468.18-343.89-242.16-170.96-150.03
Income before tax USD (M)---235.94-168.10-149.29
Income tax expense USD (M)0.00----
Net income USD (M)-446.21-317.42-235.94-168.10-149.29
Basic EPS USD/shares-3.47-3.37-3.95-3.23-
Diluted EPS USD/shares-3.47-3.37-3.95-3.23-

Dyne Therapeutics Inc Azioni (DYN) insider trading

  • Posner Brian SOct 02 '26
    Director
    Transazione
    Buy
    Costo
    $16.00
    #Azioni
    2,500
    Valore ($)
    40,000
    #Azioni Totale
    27,000
  • Cox JohnSep 08 '26
    Officer
    Transazione
    Proposed Sale
    Costo
    $18.88
    #Azioni
    5,658
    Valore ($)
    106,844
    #Azioni Totale
    0
  • Chief Commercial Officer
    Transazione
    Sale
    Costo
    $18.88
    #Azioni
    185
    Valore ($)
    3,493
    #Azioni Totale
    152,897
  • Kerr DouglasSep 08 '26
    Officer
    Transazione
    Proposed Sale
    Costo
    $18.89
    #Azioni
    35
    Valore ($)
    661
    #Azioni Totale
    0
  • Kerr DouglasSep 08 '26
    Chief Medical Officer
    Transazione
    Sale
    Costo
    $18.88
    #Azioni
    1,290
    Valore ($)
    24,355
    #Azioni Totale
    162,564
  • Cox JohnSep 08 '26
    CEO & President
    Transazione
    Sale
    Costo
    $18.88
    #Azioni
    5,658
    Valore ($)
    106,823
    #Azioni Totale
    357,507
  • Kerr DouglasSep 04 '26
    Officer
    Transazione
    Proposed Sale
    Costo
    $24.35
    #Azioni
    5,000
    Valore ($)
    121,745
    #Azioni Totale
    0
  • Kerr DouglasSep 04 '26
    Chief Medical Officer
    Transazione
    Sale
    Costo
    $24.35
    #Azioni
    3,745
    Valore ($)
    91,191
    #Azioni Totale
    163,854
  • Chief Commercial Officer
    Transazione
    Sale
    Costo
    $24.35
    #Azioni
    900
    Valore ($)
    21,915
    #Azioni Totale
    153,082
  • Shareholder
    Transazione
    Proposed Sale
    Costo
    $25.96
    #Azioni
    322,465
    Valore ($)
    8,371,191
    #Azioni Totale
    0
Commercio internoRelazioneDataTransazioneCosto#AzioniValore ($)#Azioni Totale
Posner Brian SDirectorOct 02 '26Buy$16.002,50040,00027,000
Cox JohnOfficerSep 08 '26Proposed Sale$18.885,658106,8440
Friedl-Naderer JohannaChief Commercial OfficerSep 08 '26Sale$18.881853,493152,897
Kerr DouglasOfficerSep 08 '26Proposed Sale$18.89356610
Kerr DouglasChief Medical OfficerSep 08 '26Sale$18.881,29024,355162,564
Cox JohnCEO & PresidentSep 08 '26Sale$18.885,658106,823357,507
Kerr DouglasOfficerSep 04 '26Proposed Sale$24.355,000121,7450
Kerr DouglasChief Medical OfficerSep 04 '26Sale$24.353,74591,191163,854
Friedl-Naderer JohannaChief Commercial OfficerSep 04 '26Sale$24.3590021,915153,082
Atlas Venture Opportunity FundShareholderAug 14 '26Proposed Sale$25.96322,4658,371,1910

Dyne Therapeutics Inc Borsa (DYN) Ultime notizie

Oct 23, 2026
Oct 23, 2026
Oct 22, 2026
Oct 22, 2026
Oct 22, 2026
Oct 22, 2026
Oct 06, 2026
Oct 06, 2026
Sep 30, 2026
Sep 30, 2026
Sep 29, 2026
Sep 29, 2026
Sep 19, 2026
Sep 19, 2026
Sep 19, 2026
Sep 19, 2026
Sep 17, 2026
Sep 17, 2026
Sep 17, 2026
Sep 17, 2026
Sep 17, 2026
Sep 17, 2026
Sep 17, 2026
Sep 17, 2026
Sep 11, 2026
Sep 11, 2026
Sep 11, 2026
Sep 11, 2026
Sep 10, 2026
Sep 10, 2026
Sep 10, 2026
Sep 10, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026

Simile a DYN